GT BIOPHARMA, INC. (GTBP) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
19/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinGTBP / S&P 20.10% / 15.20% |
LoseGTBP / S&P GTBP unavailable / 15.00% |
LoseGTBP / S&P -108.03% / 50.40% |
| 2026-Q11/3 |
LoseGTBP / S&P -48.03% / -4.33% |
LoseGTBP / S&P GTBP unavailable / 11.30% |
WinGTBP / S&P 69.42% / 27.70% |
| 2025-Q42/3 |
WinGTBP / S&P 33.73% / 2.65% |
LoseGTBP / S&P GTBP unavailable / 9.00% |
WinGTBP / S&P 40.86% / 13.40% |
| 2025-Q31/3 |
LoseGTBP / S&P -83.60% / 8.12% |
LoseGTBP / S&P GTBP unavailable / 4.61% |
WinGTBP / S&P 82.96% / 13.45% |
| 2025-Q22/3 |
WinGTBP / S&P 66.51% / 10.94% |
LoseGTBP / S&P GTBP unavailable / 4.83% |
WinGTBP / S&P 86.32% / 10.63% |
| 2025-Q10/3 |
LoseGTBP / S&P -29.51% / -4.27% |
LoseGTBP / S&P GTBP unavailable / 4.98% |
LoseGTBP / S&P -19.52% / 10.57% |
| 2024-Q42/3 |
WinGTBP / S&P 32.09% / 2.41% |
LoseGTBP / S&P GTBP unavailable / 5.25% |
WinGTBP / S&P 24.11% / 6.15% |
| 2024-Q30/3 |
LoseGTBP / S&P -18.41% / 5.89% |
LoseGTBP / S&P GTBP unavailable / 5.89% |
LoseGTBP / S&P -66.84% / 6.11% |
| 2024-Q20/3 |
LoseGTBP / S&P -36.12% / 4.28% |
LoseGTBP / S&P GTBP unavailable / 5.38% |
LoseGTBP / S&P -63.27% / 5.12% |
| 2024-Q10/3 |
LoseGTBP / S&P -42.09% / 10.56% |
LoseGTBP / S&P GTBP unavailable / 5.71% |
LoseGTBP / S&P -64.13% / 5.59% |
| 2023-Q40/3 |
LoseGTBP / S&P 5.81% / 11.69% |
LoseGTBP / S&P GTBP unavailable / 6.81% |
LoseGTBP / S&P GTBP unavailable / 7.78% |
| 2023-Q30/3 |
LoseGTBP / S&P -22.76% / -3.27% |
LoseGTBP / S&P GTBP unavailable / 7.52% |
LoseGTBP / S&P GTBP unavailable / -5.03% |
| 2023-Q20/3 |
LoseGTBP / S&P -43.27% / 8.74% |
LoseGTBP / S&P GTBP unavailable / 9.50% |
LoseGTBP / S&P GTBP unavailable / -8.57% |
| 2023-Q10/3 |
LoseGTBP / S&P -37.92% / 7.50% |
LoseGTBP / S&P GTBP unavailable / 10.77% |
LoseGTBP / S&P GTBP unavailable / -15.69% |
| 2022-Q40/3 |
LoseGTBP / S&P -49.66% / 7.56% |
LoseGTBP / S&P GTBP unavailable / 11.88% |
LoseGTBP / S&P GTBP unavailable / -17.99% |
| 2022-Q30/3 |
LoseGTBP / S&P -41.14% / -4.88% |
LoseGTBP / S&P GTBP unavailable / 13.47% |
LoseGTBP / S&P GTBP unavailable / -1.41% |
| 2022-Q21/3 |
WinGTBP / S&P 3.82% / -16.10% |
LoseGTBP / S&P GTBP unavailable / 13.71% |
LoseGTBP / S&P GTBP unavailable / 11.04% |
| 2022-Q10/3 |
LoseGTBP / S&P -5.57% / -4.60% |
LoseGTBP / S&P GTBP unavailable / 15.97% |
LoseGTBP / S&P GTBP unavailable / 42.23% |
| 2021-Q40/3 |
LoseGTBP / S&P -54.75% / 11.03% |
LoseGTBP / S&P GTBP unavailable / 15.00% |
LoseGTBP / S&P GTBP unavailable / 96.40% |
| 2021-Q30/3 |
LoseGTBP / S&P -56.52% / 0.58% |
LoseGTBP / S&P GTBP unavailable / 10.77% |
LoseGTBP / S&P GTBP unavailable / 69.42% |
| 2021-Q21/3 |
WinGTBP / S&P 126.61% / 8.55% |
LoseGTBP / S&P GTBP unavailable / 6.58% |
LoseGTBP / S&P GTBP unavailable / 51.81% |
| 2021-Q10/3 |
LoseGTBP / S&P -5.11% / 6.17% |
LoseGTBP / S&P GTBP unavailable / -1.06% |
LoseGTBP / S&P GTBP unavailable / 7.39% |
| 2020-Q41/3 |
WinGTBP / S&P 142.29% / 12.15% |
LoseGTBP / S&P GTBP unavailable / -3.72% |
LoseGTBP / S&P GTBP unavailable / -33.42% |
| 2020-Q31/3 |
WinGTBP / S&P 25.00% / 8.93% |
LoseGTBP / S&P GTBP unavailable / -2.04% |
LoseGTBP / S&P GTBP unavailable / -27.10% |
| 2020-Q20/3 |
LoseGTBP / S&P -8.50% / 20.54% |
LoseGTBP / S&P GTBP unavailable / -0.46% |
LoseGTBP / S&P GTBP unavailable / -27.11% |
| 2020-Q11/3 |
WinGTBP / S&P 88.89% / -19.60% |
LoseGTBP / S&P GTBP unavailable / 3.47% |
LoseGTBP / S&P GTBP unavailable / -14.75% |
| 2019-Q40/3 |
LoseGTBP / S&P -40.88% / 9.07% |
LoseGTBP / S&P GTBP unavailable / 5.36% |
LoseGTBP / S&P GTBP unavailable / 2.99% |
| 2019-Q30/3 |
LoseGTBP / S&P -41.70% / 1.70% |
LoseGTBP / S&P GTBP unavailable / 5.02% |
LoseGTBP / S&P GTBP unavailable / 0.21% |
| 2019-Q20/3 |
LoseGTBP / S&P -30.88% / 4.30% |
LoseGTBP / S&P GTBP unavailable / 6.64% |
LoseGTBP / S&P GTBP unavailable / 8.65% |
| 2019-Q11/3 |
LoseGTBP / S&P -47.69% / 13.65% |
LoseGTBP / S&P GTBP unavailable / 8.12% |
WinGTBP / S&P 10361.72% / 14.29% |
| 2018-Q41/3 |
LoseGTBP / S&P -69.02% / -13.52% |
LoseGTBP / S&P GTBP unavailable / 9.05% |
WinGTBP / S&P 10362.29% / 18.23% |
| 2018-Q32/3 |
WinGTBP / S&P 25.63% / 7.71% |
LoseGTBP / S&P GTBP unavailable / 10.21% |
WinGTBP / S&P 10366.93% / 19.06% |
| 2018-Q21/3 |
LoseGTBP / S&P -12.57% / 3.43% |
LoseGTBP / S&P GTBP unavailable / 9.03% |
WinGTBP / S&P 10367.61% / 14.46% |
| 2018-Q10/3 |
LoseGTBP / S&P GTBP unavailable / -0.76% |
LoseGTBP / S&P GTBP unavailable / 7.68% |
LoseGTBP / S&P -196565.14% / 12.46% |
| 2017-Q40/3 |
LoseGTBP / S&P GTBP unavailable / 6.64% |
LoseGTBP / S&P GTBP unavailable / 7.03% |
LoseGTBP / S&P -221885.47% / 13.82% |
| 2017-Q30/3 |
LoseGTBP / S&P GTBP unavailable / 4.48% |
LoseGTBP / S&P GTBP unavailable / 5.68% |
LoseGTBP / S&P GTBP unavailable / 17.57% |
| 2017-Q20/3 |
LoseGTBP / S&P GTBP unavailable / 3.09% |
LoseGTBP / S&P GTBP unavailable / 4.83% |
LoseGTBP / S&P GTBP unavailable / 17.74% |
| 2017-Q10/3 |
LoseGTBP / S&P GTBP unavailable / 6.07% |
LoseGTBP / S&P -100.00% / 3.67% |
LoseGTBP / S&P GTBP unavailable / 13.32% |
| 2016-Q40/3 |
LoseGTBP / S&P GTBP unavailable / 3.82% |
LoseGTBP / S&P -100.00% / 2.09% |
LoseGTBP / S&P GTBP unavailable / 7.05% |
| 2016-Q30/3 |
LoseGTBP / S&P GTBP unavailable / 3.85% |
LoseGTBP / S&P -100.00% / 0.20% |
LoseGTBP / S&P GTBP unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | GTBP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -67.70% | 20.78% |
| Annualized return | -67.70% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | GTBP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.88% | 83.14% |
| Annualized return | -74.13% | 12.86% |
10Y · 2018-03-27 to 2026-08-27
| Metric | GTBP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.96% | 319.30% |
| Annualized return | -54.79% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |